New Injection Technique Helps Repair Spinal Cord Injury

In a study in immunodeficient rats, the researchers injected two boluses of human NSCs into the subpial space of the cervical and lumbar spinal cord, respectively.

The researchers then assessed the survival, distribution, and phenotype of the transplanted cells six to eight months later. Immunofluorescence staining and mRNA sequencing analysis demonstrated a near‐complete occupation of the spinal cord by injected cells, with the transplanted NSCs preferentially acquiring glial phenotypes. In the outermost layer of the spinal cord, the injected hNSCs differentiated into glia limitans‐forming astrocytes and expressed human‐specific superoxide dismutase and laminin. The study was published on January 29, 2020, in Stem Cells Translational Medicine.

“Current spinal cell delivery techniques involve direct needle injection into the spinal parenchyma, the primary cord of nerve fibers running through the vertebral column. As such, there is an inherent risk of spinal tissue injury or intraparechymal bleeding,” said corresponding author Professor Martin Marsala, MD, of UCSD. “The new technique is less invasive, depositing injected cells into the spinal subpial space. This injection technique allows the delivery of high cell numbers from a single injection. Injected cells acquire the functional properties consistent with surrounding host cells.”

According to the researchers, the data show that the subpial cell delivery technique is highly effective in populating the entire spinal cord with injected NSCs, accelerating and improving treatment potency in cell-replacement therapies for spinal neurodegenerative disorders in which a broad repopulation by glial cells, such as oligodendrocytes or astrocytes, is desired, such as in the treatment of amyotrophic lateral sclerosis (ALS), multiple sclerosis, or spinal cord injury.

Related Links:
University of California, San Diego
Czech Academy of Sciences
University of the Ryukyus